Re phase 3 question, Phase 2b has been completed.This was agreed with the FDA prior to commencement - next step is an IND application to commence FDA where Tissue Repair and the FDA confirm the trail design/protocol, acceptable tests for clinical improvement etc and agree locations and number of patients. In short, Tissue Repair is very advanced relative to their market cap. Look at ASX comparables who have completed phase 2a and b and in planning stages for commencement of pivotal trials. Don't think there are any less than double TRPs IPO market cap, and plenty are significantly more than that.
